Suppr超能文献

伊伐布雷定在心力衰竭中的应用和适应证。

The Use and Indication of Ivabradine in Heart Failure.

机构信息

Division of Cardiovascular Medicine, The Ohio state University Wexner Medical Center, 473 W12th Avenue, Columbus, OH 43210, USA.

Division of Cardiovascular Medicine, The Ohio state University Wexner Medical Center, 473 W12th Avenue, Columbus, OH 43210, USA.

出版信息

Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18.

Abstract

Heart failure affects more than 6 million people in the United States each year and the prognosis is poor. The elevated heart rate in heart failure patents is problematic, because it increases myocardial oxygen demand, decreases myocardial perfusion, and has been associated with increased rates of hospitalization and mortality. For these reasons, heart rate reduction has long been a therapeutic target in heart failure. Ivabradine is a selective inhibitor of the sinoatrial pacemaker modulating "f-current" (I) and provides heart rate reduction that can be beneficial in patients with heart failure with reduced ejection fraction.

摘要

心力衰竭每年影响美国超过 600 万人,预后不佳。心力衰竭患者的心率升高是有问题的,因为它会增加心肌氧需求,减少心肌灌注,并与住院和死亡率的增加有关。出于这些原因,降低心率一直是心力衰竭的治疗目标。伊伐布雷定是窦房结起搏的选择性抑制剂,调节 "f 电流"(I),并提供心率降低,这对射血分数降低的心力衰竭患者有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验